Search

Author/Creator Kloos, I.

1. A NEW BCL‐2 INHIBITOR (S55746/BCL201) AS MONOTHERAPY IN PATIENTS WITH RELAPSED OR REFRACTORY NON‐HODGKIN LYMPHOMA: PRELIMINARY RESULTS OF THE FIRST‐IN‐HUMAN STUDY. (June 2017)

Authors:
Le Gouill, S.; Wermke, M.; Morschhauser, F.; Lim, S.T.; Salles, G.; Kloos, I.; de Burgat, V.; Becquart, M.; Paux, G.; Kraus‐Berthier, L.; Pennaforte, S.; Stilgenbauer, S.; Walewski, J.; Ribrag, V.
Journal:
Hematological oncology
Issue:
Volume 35(2017)Supplement 2
Page Start:
47
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗

2. P1117: THREE-YEAR FOLLOW-UP OF OUTCOMES WITH KTE-X19 IN PATIENTS WITH RELAPSED/REFRACTORY MANTLE CELL LYMPHOMA IN ZUMA-2. (23rd June 2022)

Authors:
Wang, M. L.; Munoz, J.; Goy, A.; Locke, F. L.; Jacobson, C. A.; Hill, B. T.; Timmerman, J. M.; Holmes, H.; Flinn, I. W.; Miklos, D. B.; Pagel, J. M.; Kersten, M. J.; Houot, R.; Beitinjaneh, A.; Peng, W.; Fang, X.; Shen, R. R.; Siddiqi, R.; Kloos, I.; Reagan, P. M.
Journal:
HemaSphere
Issue:
Volume 6(2022)Supplement 3
Page Start:
1007
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗

3. P1454: REAL-WORLD OUTCOMES OF BREXUCABTAGENE AUTOLEUCEL (BREXU-CEL) FOR THE TREATMENT OF RELAPSED OR REFRACTORY (R/R) MANTLE CELL LYMPHOMA (MCL) IN THE UNITED STATES (US). (23rd June 2022)

Authors:
Locke, F.; Hu, Z.-H.; Gerson, J.; Frank, M. J.; Budde, L. E.; Wang, M.; Logan, B.; Kloos, I.; Siddiqi, R.; Shah, J.; Xu, H.; Pasquini, M.
Journal:
HemaSphere
Issue:
Volume 6(2022)Supplement 3
Page Start:
1336
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗